Abstract
Objective
The objective of this study was to establish a nomogram model to predict SI in patients with cancer and further evaluate its performance.
Method
This study was performed among 390 patients in oncology departments of Affiliated Hospital of Nantong University from April 2020 to January 2021. Of these, eligible patients who were diagnosed with cancer were split into training and validation cohorts according the ratio of 2:1 randomly. In the training cohort, multivariate regression was performed to determine the independent variables related to SI. A nomogram was built incorporating these variables. The model performance was evaluated by an independent validation cohort.
Results
The prevalence of SI in patients with cancer was 22.31% and 19.23% in training and validation cohorts, respectively. The nomogram model suggested independent variables for SI, including depression, emotional function, time after diagnosis, family function and educational status. The area under the curve (AUC) was 0.93 (95%CI, 0.90–0.97) and 0.82 (95%CI, 0.74–0.90) in training and validation cohorts respectively, which indicated good discrimination of the nomogram in predicting SI in cancer patients. The p-value of the goodness of fit (GOF) test was 0.197 and 0.974 in training and validation cohorts respectively, suggesting our nomogram model has acceptable calibration power, and the calibration curves further indicated good calibration power.
Conclusion
In conclusion, the nomogram model for predicting individualized probability of SI could help clinical caregivers estimate the risk of SI in patients with cancer and provide appropriate management.
ACKNOWLEDGMENTS
The authors sincerely thank all the participants in this study.
DISCLOSURE STATEMENT
No potential conflict of interest was reported by the author(s).
Additional information
Funding
Notes on contributors
Lin Du
Lin Du, School of Medicine, Nantong University, Nantong, Jiangsu, PR China.
Hai-Yan Shi
Hai-Yan Shi, Department of Thoracic Oncology, The Rugao People's Hospital, Nantong, Jiangsu, PR China.
Yan- Qian
Yan- Qian and Xiao-Hong Jin, Department of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, PR China.
Xiao-Hong Jin
Yan- Qian and Xiao-Hong Jin, Department of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, PR China.
Hai-Rong Yu
Hai-Rong Yu, Department of Thoracic Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, PR China.
Xue-Lei Fu
Xue-Lei Fu and Hua Wu, School of Medicine, Nantong University, Nantong, Jiangsu, PR China.
Hua Wu
Xue-Lei Fu and Hua Wu, School of Medicine, Nantong University, Nantong, Jiangsu, PR China.
Hong-Lin Chen
Hong-Lin Chen, School of Public Health, Nantong University, Nantong, Jiangsu, PR China.